Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants

Clinical Infectious Diseases

Volumn 26, Issue 6, 1998, Pages 1282-1289

  Giles, Francis Joseph ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; CEPHALOSPORIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; IDARUBICIN; MITOXANTRONE; PENICILLIN G; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CELL PROLIFERATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG TOXICITY; MACROPHAGE; MAJOR CLINICAL STUDY; MONOCYTE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; STEM CELL TRANSPLANTATION; SURVIVAL TIME;

EID: 0031865499     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516361     Document Type: Review

References (25)

1. Rowe JM, Liesveld JL. Treatment and prognostic factors in acute myeloid leukemia. Clin Haematol 1996;9:87-105.
2. Keating MJ. New approaches in the treatment of AML and MDS. In: Hiddemann W, Büchner T, Wörmann B, et al., eds. Acute leukemias V. New York: Springer, 1996:187-94.
3. Keating MJ, Cork A, Broach Y, et al. Towards a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res 1987;11: 119-33.
4. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841-51.
5. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post-remission therapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-1.
6. Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, doubleblind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:949-54.
7. DeWitte T, Gratwohl A, Van Der Lely N, et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 1992;79:1359-65.
8. O'Day SJ, Rabinowe SN, Neuberg D, et al. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. Blood 1994;83:2707-14.
9. Hamm J, Schiller JH, Cuffie C, et al. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994;12:2667-76.
10. Kantarjian HM, Estey EH, O'Brien S, et al. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by human granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood 1992;79:876-81.
11. Giles FJ. Current status of blood cell transplantation. Forum - Trends in Experimental Clinical Medicine 1996;6:66-79.
12. Siena S. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colonystimulating factor (GM-CSF). Blood 1989;74:1905-14.
13. Griffin JD, Young D, Herrmann F, et al. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 1986;67:1448-53.
14. Miyauchi J, Kelleher CA, Yang Y, et al. The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 1987;70:657-63.
15. Boogaerts MA, Verhoef GEG, Demuynck H. Treatment and prognostic factors in myelodysplastic syndromes. Clin Haematol 1996;9:161-84.
16. Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996;14:1371-82.
17. Rose C, Wattel E, Bastion Y, et al. Treatment with very low-dose GMCSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia 1994;8:1458-62.
18. Vadhan-Raj S, Keating M, LeMaitre A, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987;317:1545-52.
19. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF versus observation for myelodysplastic syndromes. Blood 1993;82 (supp 1):196a.
20. Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C plus daunorubicin: comparison to patients treated without GM-CSF. Blood 1992;79:2246-55.
21. Büchner T, Hiddemann W, Rottmann R, et al. Multiple course chemotherapy with or without GM-CSF priming and long-term administration for . newly diagnosed AML. Proceedings of the American Society for Clinical Oncology 1993;12:301a.
22. Estey E. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 1994;83:2015-9.
23. Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994;83: 2086-92.
24. Büchner T, Hiddemann W, Koenigsmann M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991;78:1190-6.
25. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-62.